What Viridian Therapeutics’ Latest Earnings Mean For Investors

Viridian Therapeutics (VRDN) reported its second quarter and six month results to June 30, 2026, giving investors fresh detail on revenue and losses that appear to be driving recent stock interest.

Quarterly revenue was US$0.284 million compared with US$0.075 million a year earlier. Net loss for the period was US$127.12 million, with basic loss per share from continuing operations at US$1.05 compared with US$1 in the prior year quarter.

Across the first half of 2026, Viridian Therapeutics reported revenue of US$0.425 million compared with US$0.147 million a year earlier. Net loss for the six months was US$232.02 million and basic loss per share from continuing operations was US$1.95 compared with US$1.87 a year earlier.

Viridian Therapeutics’ latest earnings update arrived alongside a sharp shift in momentum, with a 1-day share price return of 3.64% and a 30-day share price return of 32.72%, even though the year to date share price return is down 22%. Over a longer horizon, total shareholder return of 34.36% over one year and 76.87% over five years suggests investors willing to tolerate recent losses and volatility have still seen gains. This helps explain why fresh earnings data can quickly move the stock at the current US$23.93 share price.

If the swing in Viridian Therapeutics has you thinking about other high growth healthcare names, this is a good moment to see which companies are catching attention in the 42 healthcare AI stocks.

After Viridian Therapeutics’ sharp recent move and ongoing losses, the key question is whether to lock in exposure now or wait for a potentially cheaper entry point. To assess that choice, it helps to look closely at where the valuation stands next.

Preferred Price-to-Sales Multiple of 38.1x: Is It Justified For Viridian Therapeutics?

Viridian Therapeutics closed at $23.93, and current valuation checks point to a very rich price to sales profile compared with both peers and an estimated fair level. The stock is flagged as trading at an 83% discount to an SWS DCF fair value estimate of $140.56, yet on a simple revenue multiple it is described as expensive.

The preferred metric used here is the P/S ratio, which compares Viridian Therapeutics’ market value with its reported revenue. For early stage biotech companies that are still loss making, investors often lean on revenue and pipeline expectations rather than earnings based measures, so the P/S ratio can become a quick shorthand for how much future success is already reflected in the share price.

For Viridian Therapeutics, the P/S ratio of 38.1x is described as expensive relative to several yardsticks. It is higher than the estimated fair P/S ratio of 0.1x, which suggests a very large gap between current pricing and the level that regression based modelling points to as more typical for companies with similar characteristics. It is also higher than the US biotechs industry average of 11.3x and a peer group average of 9x, which indicates the market is placing a much bigger premium on Viridian Therapeutics’ revenue base than on comparable stocks, even though the company is still reporting losses.

Explore the SWS fair ratio for Viridian Therapeutics.

Result: Price-to-Sales of 38.1x (OVERVALUED)

However, investors in Viridian Therapeutics still face real risk that ongoing losses and any setbacks in its rare disease pipeline could quickly challenge the current valuation.

Another View On Viridian Therapeutics’ Valuation

The earlier P/S discussion painted Viridian Therapeutics as expensive, yet the SWS DCF model points in the opposite direction. At a share price of $23.93, VRDN is described as trading at an 83% discount to an estimated future cash flow value of $140.56 per share. That leaves investors asking which signal deserves more weight.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Viridian Therapeutics for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 50 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

With Viridian Therapeutics showing both sharp recent moves and ongoing losses, sentiment is clearly mixed. It helps to look at the detail yourself and decide where you stand. To see both the potential upsides and the areas of concern in one place, review the 2 key rewards and 1 important warning sign.

Looking For More Investment Ideas Beyond Viridian Therapeutics?

If Viridian Therapeutics has sharpened your focus on where you want your money working, do not stop here. Broader ideas can help balance conviction and risk.

• Target resilient cash generators that still trade at what looks like a discount by scanning 50 high quality undervalued stocks that match your quality and value filters.
• Strengthen the defensive side of your portfolio by reviewing solid balance sheet and fundamentals stocks screener (50 results) that pair robust finances with fundamental support.
• Look for potential opportunities by reviewing screener containing 20 high quality undiscovered gems before they attract wider attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.